bioAffinity Technologies, Inc. (BIAF): Revenue
$6.16M
Year ended 2025-12-31
$5.90M
Trailing 12 months to 2026-06-30
-3.7%
3-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.16M | -34.2% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $9.36M | +269.7% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $2.53M | -63.3% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $6.90M | n/a | 2024-04-01, From 2022-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | $6.16M | -34.2% |
| Absci Corp (ABSI) | 2025-12-31 | $2.80M | -38.2% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $16.37M | +304.0% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $18.67M | -29.3% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | $1.93M | -79.2% |
| OneMedNet Corp (ONMD) | 2025-12-31 | $1.36M | +111.4% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $33.03M | -14.5% |
| Cannabis Bioscience International Holdings, Inc. (CBIH) | 2025-05-31 | $303.0K | +21.8% |
| NRC Health (NRC) | 2025-12-31 | $137.39M | -4.0% |
Compare BIAF, ABSI, FOXO, OABI side by side · Screen every company in Services-Commercial Physical & Biological Research ↗